A company is only as good as its employees. Accordingly, companies are interested in qualified, motivated, and loyal employees. However, these are not a dime a dozen - and so employers have to rethink and ask themselves not only what (potential) employees can do for them, but also: "How can I find good employees and, above all, keep them for the long term?" Read our blog post to find out what matters to employees in their jobs these days - and what emovis does to improve and maintain employee satisfaction.
Part 1 of our interview with Dr. Guido Koopmans from Algiax Pharmaceuticals GmbH is about the complex clinical picture of neuropathy and the phase IIa study currently underway on the promising active substance AP-325. In the second part you will learn, among other things, what experiences sparked the fire in Dr. Koopmans to go into science and what a "typical" working day is like for him.
Neuropathic pain is not "normal" pain – its treatment is considered complex and challenging. A promising phase II study is currently being conducted on behalf of Algiax Pharmaceuticals GmbH: Hopes are pinned on a new compound called AP-325. We at emovis are pleased to be one of the many study sites who have been invited to participate in this trial.
Read the first part of our interview with Dr. Guido Koopmans, developer of AP-325 and sponsor of the associated study: You will learn what makes his compound so special and what research results are already available on it.